A case report of hereditary leiomyomatosis and renal cell carcinoma (HLRCC)

Sunao Nohara,Shotaro Nakanishi, Tomoki Matsuo,Tomoko Tamaki, Seiici Saito

Urology Case Reports(2024)

引用 0|浏览0
暂无评分
摘要
Leiomyomatosis and renal cell carcinoma (HLRCC) are rare autosomal dominant cancer syndromes characterized by cutaneous leiomyoma, uterine leiomyoma, and renal cell carcinoma (RCC). RCC in HLRCC is an aggressive metastatic tumor that develops at a young age. Here, we report the case of a patient with HLRCC who was diagnosed after the spontaneous rupture of a renal tumor. The patient underwent cytoreductive surgery, followed by combination therapy with the immune checkpoint inhibitor (ICI) nivolumab and cabozantinib, a tyrosine kinase inhibitor (TKI); however, no improvements were achieved.
更多
查看译文
关键词
leiomyomatosis,renal cell carcinoma,fumarate hydratase,cytoreductive surgery,immune checkpoint inhibitor,tyrosine kinase inhibitor
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要